Phase 1–2 study of docetaxel plus aflibercept in patients with recurrent ovarian, primary peritoneal, or fallopian tube cancer

BACKGROUND: Biologically targeted therapies have been postulated as a viable strategy to improve outcomes for women with ovarian cancer. We assessed the safety, tolerance, pharmacokinetics, relevant circulating and image-derived biomarkers, and clinical activity of combination aflibercept and doceta...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Coleman, Robert L, Duska, Linda R, Ramirez, Pedro T, Heymach, John V, Kamat, Aparna A, Modesitt, Susan C, Schmeler, Kathleen M, Iyer, Revathy B, Garcia, Michael E, Millera, Debbie L, Jackson, Edward F, Ng, Chaan S, Kundra, Vikas, Jaffe, Robert, Sood, Anil K
Formato: Artigo
Idioma:Inglês
Publicado em: 2011
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3444811/
https://ncbi.nlm.nih.gov/pubmed/21992853
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1470-2045(11)70244-3
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados